US2021079002A1PendingUtilityA1

Heteroaryl pyridone and aza-pyridone compounds

76
Assignee: GENENTECH INCPriority: Nov 3, 2011Filed: Aug 24, 2020Published: Mar 18, 2021
Est. expiryNov 3, 2031(~5.3 yrs left)· nominal 20-yr term from priority
Inventors:James John CrawfordDaniel Fred OrtwineBinqing WeiWendy B. Young
C07F 7/1804C07D 405/14C07D 401/14A61K 31/496A61K 31/501A61P 37/00C07D 487/08A61K 31/5383C07D 495/14A61K 31/5025A61K 31/4985C07D 519/00C07D 495/04C07D 513/04C07D 471/14C07D 487/04A61K 31/495A61K 31/4995A61K 31/497C07D 471/04C07D 487/14A61K 31/506A61K 31/5377C07D 498/04A61K 31/53A61K 9/20A61P 35/00A61K 45/06
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Claims

exact text as granted — not AI-modified
1 .- 27 . (canceled) 
     
     
         28 . A compound, wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         29 . A compound, wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         30 . A compound, wherein the compound is:

Join the waitlist — get patent alerts

Track US2021079002A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.